EMulate Therapeutics, Inc. (EMTX)

EMulate Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	0.01	0.35	0.12
Cash & Cash Equivalents	0.01	0.35	0.12
Cash Growth	-	194.87%	-
Other Current Assets	0.07	0	0.17
Total Current Assets	0.19	0.35	0.28
Property, Plant & Equipment	-	0.13	0.28
Long-Term Investments	-	6.69	14.78
Goodwill and Intangibles	-	0.37	0.6
Other Long-Term Assets	-	0.2	0.2
Total Long-Term Assets	-	7.39	15.86
Total Assets	-	7.74	16.14
Accounts Payable	-	2.76	2.82
Current Debt	-	8.26	5.86
Other Current Liabilities	19.94	28.26	26.67
Total Current Liabilities	19.94	39.27	35.36
Long-Term Debt	-	1.04	1.21
Other Long-Term Liabilities	-	14.58	14.44
Total Long-Term Liabilities	-	15.61	15.65
Total Liabilities	-	54.89	51.01
Total Debt	10.21	9.3	7.07
Debt Growth	-	31.52%	-
Retained Earnings	-	-168.51	-146.42
Shareholders' Equity	-23.91	-47.15	-34.86
Net Cash / Debt	-10.2	-8.95	-6.95
Working Capital	-19.75	-38.93	-35.07

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).